Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with Boston-based Bach BioSciences, to exploit the potential of the Affimer platform for the development of a novel class of drug conjugates.
30 Jul 2018
Avacta Group - Exciting partnership with Bach BioSciences
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Avacta Group - Exciting partnership with Bach BioSciences
Avacta Group PLC (AVCT:LON) | 43.2 -0.6 (-3.0%) | Mkt Cap: 151.6m
- Published:
30 Jul 2018 -
Author:
Dr. Riccardo Lowi -
Pages:
4
Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with Boston-based Bach BioSciences, to exploit the potential of the Affimer platform for the development of a novel class of drug conjugates.